The DOI matches its Crossref record; 161 of the 161 references it cites were found in a registry or an index.
Melanoma treatment in review
Open accessAbstract
Melanoma represents the most aggressive and the deadliest form of skin cancer. Current therapeutic approaches include surgical resection, chemotherapy, photodynamic therapy, immunotherapy, biochemotherapy, and targeted therapy. The therapeutic strategy can include single agents or combined therapies, depending on the patient's health, stage, and location of the tumor. The efficiency of these treatments can be decreased due to the development of diverse resistance mechanisms. New therapeutic targets have emerged from studies of the genetic profile of melanocytes and from the identification of molecular factors involved in the pathogenesis of the malignant transformation. In this review, we aim to survey therapies approved and under evaluation for melanoma treatment and relevant research on the molecular mechanisms underlying melanomagenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Dougherty, T. J., Gomer, C. J., Henderson, B. W., Jori, G., Kessel, D., Korbelik, M., Moan, J., & Peng, Q. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.12.889 · Cited by 4,716
Gomer, C. J. (1988) · Cited by 4,169
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Cancer treatment and survivorship statistics, 2022
Miller, K. D., Nogueira, L., Devasia, T., Mariotto, A. B., Yabroff, K. R., Jemal, A., Kramer, J., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21731 · Cited by 3,597
Folkman, J., & Klagsbrun, M. (1987) · Science · doi:10.1126/science.2432664 · Cited by 3,491
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335 · cited 1×
“114 The most common BCT approach uses as chemotherapy a combination of dacarbazine, cisplatin (an antitumoral agent that induces DNA damage and apoptotic signals 115 ), and vinblastine (a microtubule targeting agent 116 ), with IL-2 and IFN α -2b as immunotherapy.”
Nanoparticles in Photodynamic Therapy
Lucky, S. S., Soo, K. C., & Zhang, Y. (2015) · Chemical Reviews · doi:10.1021/cr5004198 · Cited by 2,980
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012
Stimpfel, M., & Virant-Klun, I. (2016) · Journal of Cancer Stem Cell Research · doi:10.14343/jcscr.2016.4e1003 · Cited by 2,540
HOW DOES PHOTODYNAMIC THERAPY WORK?
Henderson, B. W., & Dougherty, T. J. (1992) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1992.tb04222.x · Cited by 2,358
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C.-J., Van den Abbeele, A. D., Druker, B. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.190 · Cited by 2,299
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068
Pestka, S., Langer, J. A., Zoon, K. C., & Samuel, C. E. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.003455 · Cited by 1,825
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774
The present and future role of photodynamic therapy in cancer treatment
Brown, S. B., Brown, E. A., & Walker, I. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01529-3 · Cited by 1,771
Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,639
Somatic Activation of KIT in Distinct Subtypes of Melanoma
Curtin, J. A., Busam, K., Pinkel, D., & Bastian, B. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2984 · Cited by 1,616
Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,572
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Melanoma biology and new targeted therapy
Gray-Schopfer, V., Wellbrock, C., & Marais, R. (2007) · Nature · doi:10.1038/nature05661 · Cited by 1,371
Dudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5449 · Cited by 1,332
A new member of the immunoglobulin superfamily—CTLA-4
Brunet, J.-F., Denizot, F., Luciani, M.-F., Roux-Dosseto, M., Suzan, M., Mattei, M.-G., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,306
Middleton, M. R., Grob, J. J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M., Aamdal, S., Cebon, J., Coates, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.158 · Cited by 1,272
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Natural and Adaptive Foxp3+ Regulatory T Cells: More of the Same or a Division of Labor?
Curotto de Lafaille, M. A., & Lafaille, J. J. (2009) · Immunity · doi:10.1016/j.immuni.2009.05.002 · Cited by 1,055
BRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
Gattinoni, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24480 · Cited by 958
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C., Petruzzelli, L., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.17 · Cited by 953
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function
Sukumar, M., Liu, J., Ji, Y., Subramanian, M., Crompton, J. G., Yu, Z., Roychoudhuri, R., Palmer, D. C., Muranski, P., Karoly, E. D., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69589 · Cited by 952
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Schwartzentruber, D. J., Lawson, D. H., Richards, J. M., Conry, R. M., Miller, D. M., Treisman, J., Gailani, F., Riley, L., Conlon, K., Pockaj, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012863 · Cited by 911
Marty, M., Sersa, G., Garbay, J. R., Gehl, J., Collins, C. G., Snoj, M., Billard, V., Geertsen, P. F., Larkin, J. O., Miklavcic, D., et al. (2006) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2006.08.002 · Cited by 908
Kirkwood, J. M., Ibrahim, J. G., Sosman, J. A., Sondak, V. K., Agarwala, S. S., Ernstoff, M. S., & Rao, U. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2370 · Cited by 898
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869
The mTOR Signalling Pathway in Human Cancer
Pópulo, H., Lopes, J. M., & Soares, P. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13021886 · Cited by 830
Self-citationApoptosis and melanoma chemoresistance
Soengas, M. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1206454 · Cited by 826
Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-00462-8 · Cited by 757
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Dummer, R., Hauschild, A., Guggenheim, M., Keilholz, U., & Pentheroudakis, G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds229 · Cited by 714
A cell biological view of Toll-like receptor function: regulation through compartmentalization
Barton, G. M., & Kagan, J. C. (2009) · Nature Reviews Immunology · doi:10.1038/nri2587 · Cited by 709
Cell Death Pathways in Photodynamic Therapy of Cancer
Mroz, P., Yaroslavsky, A., Kharkwal, G. B., & Hamblin, M. R. (2011) · Cancers · doi:10.3390/cancers3022516 · Cited by 704
John, L. B., Devaud, C., Duong, C. P. M., Yong, C. S., Beavis, P. A., Haynes, N. M., Chow, M. T., Smyth, M. J., Kershaw, M. H., & Darcy, P. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0458 · Cited by 694
Guo, J., Si, L., Kong, Y., Flaherty, K. T., Xu, X., Zhu, Y., Corless, C. L., Li, L., Li, H., Sheng, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9275 · Cited by 688
Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., Blank, C. U., Hauschild, A., Beck, J. T., St-Pierre, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70024-x · Cited by 640 · cited 1×
“MEK is a downstream target of BRAF and, in contrast to the BRAF inhibitors, MEK inhibitors showed activity in NRAS-mutant melanomas.(130) Trametinib, a pharmacological MEK1/2 inhibitor with antitumoral activity, was approved (2013) as a monotherapy by the FDA for the treatment of unresectable or metastatic malignant m…”
Eggermont, A. M., Suciu, S., Santinami, M., Testori, A., Kruit, W. H., Marsden, J., Punt, C. J., Salès, F., Gore, M., MacKie, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61033-8 · Cited by 640
Jackson, H. J., Rafiq, S., & Brentjens, R. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.36 · Cited by 613
Hodi, F. S., Corless, C. L., Giobbie-Hurder, A., Fletcher, J. A., Zhu, M., Marino-Enriquez, A., Friedlander, P., Gonzalez, R., Weber, J. S., Gajewski, T. F., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7836 · Cited by 608
Garbe, C., Peris, K., Hauschild, A., Saiag, P., Middleton, M., Bastholt, L., Grob, J.-J., Malvehy, J., Newton-Bishop, J., Stratigos, A. J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.05.005 · Cited by 605
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Rizos, H., Menzies, A. M., Pupo, G. M., Carlino, M. S., Fung, C., Hyman, J., Haydu, L. E., Mijatov, B., Becker, T. M., Boyd, S. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3122 · Cited by 547
Treatment of metastatic melanoma: an overview.
Bhatia, S., Tykodi, S. S., & Thompson, J. A. (2009) · PubMed · Cited by 537
Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
Gide, T. N., Wilmott, J. S., Scolyer, R. A., & Long, G. V. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2267 · Cited by 454
Major Response to Imatinib Mesylate in KIT-Mutated Melanoma
Hodi, F. S., Friedlander, P., Corless, C. L., Heinrich, M. C., Mac Rae, S., Kruse, A., Jagannathan, J., Van den Abbeele, A. D., Velazquez, E. F., Demetri, G. D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0707 · Cited by 419
Goff, S. L., Dudley, M. E., Citrin, D. E., Somerville, R. P., Wunderlich, J. R., Danforth, D. N., Zlott, D. A., Yang, J. C., Sherry, R. M., Kammula, U. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.7220 · Cited by 407
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Dummer, R., Hauschild, A., Lindenblatt, N., Pentheroudakis, G., & Keilholz, U. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv297 · Cited by 396
First oncolytic virus approved for melanoma immunotherapy
Pol, J., Kroemer, G., & Galluzzi, L. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1115641 · Cited by 392
Krieg, C., Létourneau, S., Pantaleo, G., & Boyman, O. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002569107 · Cited by 380
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
Program, N. C. S., Prickett, T. D., Agrawal, N. S., Wei, X., Yates, K. E., Lin, J. C., Wunderlich, J. R., Cronin, J. C., Cruz, P., Rosenberg, S. A., et al. (2009) · Nature Genetics · doi:10.1038/ng.438 · Cited by 352
Emerging concepts of T cell metabolism as a target of immunotherapy
Chang, C.-H., & Pearce, E. L. (2016) · Nature Immunology · doi:10.1038/ni.3415 · Cited by 338
Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers
Widakowich, C., de Castro, G., de Azambuja, E., Dinh, P., & Awada, A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1443 · Cited by 324
Chimeric antigen receptor T cells: a novel therapy for solid tumors
Yu, S., Li, A., Liu, Q., Li, T., Yuan, X., Han, X., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0444-9 · Cited by 306
Attia, P., Maker, A. V., Haworth, L. R., Rogers-Freezer, L., & Rosenberg, S. A. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000175468.19742.10 · Cited by 286
Mutations associated with familial melanoma impair p16INK4 function
Ranade, K., Hussussian, C. J., Sikorski, R. S., Varmus, H. E., Goldstein, A. M., Tucker, M. A., Serrano, M., Hannon, G. J., Beach, D., & Dracopoli, N. C. (1995) · Nature Genetics · doi:10.1038/ng0595-114 · Cited by 280 · cited 2×
“156 159 Beyond CDK4, CDK6 and cyclins (D1, D2, or D3) also control the point in G1.”
Immunotherapy in melanoma: Recent advances and future directions
Franklin, C., Livingstone, E., Roesch, A., Schilling, B., & Schadendorf, D. (2017) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2016.07.145 · Cited by 278
Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
Jacobs, J. F., Nierkens, S., Figdor, C. G., de Vries, I. J. M., & Adema, G. J. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70155-3 · Cited by 245
Hoeflich, K. P., Merchant, M., Orr, C., Chan, J., Den Otter, D., Berry, L., Kasman, I., Koeppen, H., Rice, K., Yang, N.-Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1515 · Cited by 242
Willmore-Payne, C., Holden, J. A., Tripp, S., & Layfield, L. J. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.03.015 · Cited by 230
Hereditary melanoma: Update on syndromes and management
Soura, E., Eliades, P. J., Shannon, K., Stratigos, A. J., & Tsao, H. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.08.038 · Cited by 230
Miklavčič, D., Serša, G., Brecelj, E., Gehl, J., Soden, D., Bianchi, G., Ruggieri, P., Rossi, C. R., Campana, L. G., & Jarm, T. (2012) · Medical & Biological Engineering & Computing · doi:10.1007/s11517-012-0991-8 · Cited by 229
Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
Atefi, M., von Euw, E., Attar, N., Ng, C., Chu, C., Guo, D., Nazarian, R., Chmielowski, B., Glaspy, J. A., Comin-Anduix, B., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028973 · Cited by 227
Human melanocyte senescence and melanoma susceptibility genes
Bennett, D. C. (2003) · Oncogene · doi:10.1038/sj.onc.1206446 · Cited by 212
Trametinib: First Global Approval
Wright, C. J. M., & McCormack, P. L. (2013) · Drugs · doi:10.1007/s40265-013-0096-1 · Cited by 206
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
Zhang, E., & Xu, H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0379-6 · Cited by 194
Han, Y., Guo, Q., Zhang, M., Chen, Z., & Cao, X. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.111 · Cited by 187
CAR T Cell Therapy: A Game Changer in Cancer Treatment
Almåsbak, H., Aarvak, T., & Vemuri, M. C. (2016) · Journal of Immunology Research · doi:10.1155/2016/5474602 · Cited by 183
Panelli, M. C., Wunderlich, J., Jeffries, J., Wang, E., Mixon, A., Rosenberg, S. A., & Marincola, F. M. (2000) · Journal of Immunotherapy · doi:10.1097/00002371-200007000-00013 · Cited by 180
Wilson, M. A., & Schuchter, L. M. (2016) · Cancer Treatment and Research · doi:10.1007/978-3-319-22539-5_8 · Cited by 179
Ives, N. J., Suciu, S., Eggermont, A. M. M., Kirkwood, J., Lorigan, P., Markovic, S. N., Garbe, C., Wheatley, K., Bufalino, R., Cameron, D., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.006 · Cited by 174
Sabatino, M., Kim-Schulze, S., Panelli, M. C., Stroncek, D., Wang, E., Taback, B., Kim, D. W., DeRaffele, G., Pos, Z., Marincola, F. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1106 · Cited by 171
Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
Melero, I., Grimaldi, A. M., Perez-Gracia, J. L., & Ascierto, P. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2214 · Cited by 170
Management of cutaneous metastases using electrochemotherapy
Matthiessen, L. W., Chalmers, R., Sainsbury, D. C. G., Veeramani, S., Kessell, G., Humphreys, A. C., Bond, J. E., Muir, T., & Gehl, J. (2011) · Acta Oncologica · doi:10.3109/0284186x.2011.573626 · Cited by 153
Human Melanocyte Biology, Toxicology, and Pathology
Tolleson, W. H. (2005) · Journal of Environmental Science and Health Part C · doi:10.1080/10590500500234970 · Cited by 151
Raedler, L. A. (2015) · PubMed · Cited by 151
Melanoma resistance to photodynamic therapy: new insights
Huang, Y., Vecchio, D., Avci, P., Yin, R., García-Díaz, M., & Hamblin, M. R. (2012) · Biological Chemistry · doi:10.1515/hsz-2012-0228 · Cited by 150
Dabrafenib: First Global Approval
Ballantyne, A. D., & Garnock-Jones, K. P. (2013) · Drugs · doi:10.1007/s40265-013-0095-2 · Cited by 146
Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy
Niezgoda, A., Niezgoda, P., & Czajkowski, R. (2015) · BioMed Research International · doi:10.1155/2015/851387 · Cited by 145
Monge‐Fuentes, V., Muehlmann, L. A., Longo, J. P. F., Silva, D., Fascineli, M. L., Souza, P. D., Faria, F., Degterev, I. A., Rodriguez, A. F. R., Carneiro, F. P., et al. (2016) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2016.12.002 · Cited by 143
Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells
Yvon, E. S., Vecchio, M. D., Savoldo, B., Hoyos, V., Dutour, A., Anichini, A., Dotti, G., & Brenner, M. K. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3163 · Cited by 141
Ribas, A., Comín-Anduix, B., Economou, J. S., Donahue, T. R., de la Rocha, P., Morris, L. F., Jalil, J., Dissette, V. B., Shintaku, I. P., Glaspy, J. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0783 · Cited by 135
Targeted therapy for melanoma: rational combinatorial approaches
Kwong, L. N., & Davies, M. A. (2013) · Oncogene · doi:10.1038/onc.2013.34 · Cited by 133
Yadav, V., Burke, T. F., Huber, L., Van Horn, R. D., Zhang, Y., Buchanan, S. G., Chan, E. M., Starling, J. J., Beckmann, R. P., & Peng, S.-B. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0257 · Cited by 132
Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions
Batus, M., Waheed, S., Ruby, C. E., Petersen, L. F., Bines, S. D., & Kaufman, H. L. (2013) · American Journal of Clinical Dermatology · doi:10.1007/s40257-013-0025-9 · Cited by 131
Photodynamic therapy in melanoma--an update.
Bâldea, I., & Filip, G. A. (2012) · PubMed · Cited by 130
Recent advances in targeted nanoparticles drug delivery to melanoma
Li, J., Wang, Y., Liang, R., An, X., Wang, K., Shen, G., Tu, Y., Zhu, J., & Tao, J. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.11.006 · Cited by 127
A new era: melanoma genetics and therapeutics
Ko, J., & Fisher, D. E. (2010) · The Journal of Pathology · doi:10.1002/path.2804 · Cited by 127
Role and therapeutic potential of PI3K‐mTOR signaling in de novo resistance to BRAF inhibition
Deng, W., Gopal, Y. N. V., Scott, A., Chen, G., Woodman, S. E., & Davies, M. A. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00950.x · Cited by 113
Jiang, B., Zhang, L., Guo, X., Shen, X., Wang, Y., Zhu, Y., & Liang, H. (2016) · Small · doi:10.1002/smll.201602496 · Cited by 105
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays
Mehnert, J. M., McCarthy, M. M., Jilaveanu, L. B., Flaherty, K. T., Aziz, S. A., Camp, R. L., Rimm, D. L., & Kluger, H. M. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.08.016 · Cited by 101
The role of the tumour microenvironment in immunotherapy
Gasser, S., Lim, L. H. K., & Cheung, F. S. G. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0146 · Cited by 95
von Moos, R., Seifert, B., Simcock, M., Goldinger, S. M., Gillessen, S., Ochsenbein, A. F., Michielin, O. A., Cathomas, R. L., Schläppi, M., Moch, H., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr126 · Cited by 93
The scope of nanoparticle therapies for future metastatic melanoma treatment
Bombelli, F. B., Webster, C. A., Moncrieff, M. D., & Sherwood, V. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70333-4 · Cited by 92
Eggermont, A. M. M., Suciu, S., Rutkowski, P. L., Kruit, W., Punt, C. J. A., Dummer, R., Salès, F., Keilholz, U., de Schaetzen, G., & Testori, A. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.014 · Cited by 86
Distinct sets of genetic alterations in melanoma
Margolin, K. A. (2006) · Current Oncology Reports · doi:10.1007/s11912-006-0064-y · Cited by 83
BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management.
Livingstone, E., Zimmer, L., Vaübel, J., & Schadendorf, D. (2014) · PubMed · doi:10.3978/j.issn.2304-3865.2014.03.03 · Cited by 82
Yuan, J. D., Ku, G. Y., Gallardo, H. F., Orlandi, F., Manukian, G., Rasalan, T. S., Xu, Y., Li, H., Vyas, S., Mu, Z., et al. (2009) · PubMed · Cited by 79
Telang, S., Rasku, M. A., Clem, A. L., Carter, K., Klarer, A. C., Badger, W. R., Milam, R. A., Rai, S. N., Pan, J., Gragg, H., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-515 · Cited by 76
Adoptive Cell Therapy for Metastatic Melanoma
Merhavi-Shoham, E., Itzhaki, O., Markel, G., Schachter, J., & Besser, M. J. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000240 · Cited by 71
Rarity of CDK4 germline mutations in familial melanoma
Goldstein, A. M., Chidambaram, A., Halpern, A. C., Holly, E. A., Guerry, D., Sagebiel, R. W., Elder, D. E., & Tucker, M. A. (2002) · Melanoma Research · doi:10.1097/00008390-200202000-00008 · Cited by 67
Flaherty, K. T. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-050410-105655 · Cited by 67
Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature
Gençler, B., & Gönül, M. (2016) · Dermatology Research and Practice · doi:10.1155/2016/5361569 · Cited by 65
(Neo)adjuvant systemic therapy for melanoma
van Zeijl, M. C. T., van den Eertwegh, A. J. M., Haanen, J. B. A. G., & Wouters, M. W. J. M. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.07.001 · Cited by 65
Mechanisms of kinetic stabilization by the drugs paclitaxel and vinblastine
Castle, B., McCubbin, S., Prahl, L. S., Bernens, J. N., Sept, D., & Odde, D. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e16-08-0567 · Cited by 65
Intralesional immunotherapy for melanoma
Hersey, P., & Gallagher, S. J. (2013) · Journal of Surgical Oncology · doi:10.1002/jso.23494 · Cited by 57
Insights into melanoma: targeting the mTOR pathway for therapeutics
Pópulo, H., Soares, P., & Lopes, J. M. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.691472 · Cited by 49
Self-citationPhotodynamic Therapy of Human Malignant Melanoma Xenografts in Athymic Nude Mice1
Nelson, J. S., McCullough, J. L., & Berns, M. W. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.1.56 · Cited by 48
mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics
Pópulo, H., Soares, P., Faustino, A., Rocha, A. S., Silva, P., Azevedo, F., & Lopes, J. M. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00796.x · Cited by 47
Self-citationAbildgaard, C., Dahl, C., Basse, A. L., Ma, T., & Guldberg, P. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0247-5 · Cited by 46
Bright, R., Coventry, B. J., Eardley-Harris, N., & Briggs, N. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000149 · Cited by 45
Ontak-like human IL-2 fusion toxin
Wang, Z., Zheng, Q., Zhang, H., Bronson, R. T., Madsen, J. C., Sachs, D. H., Huang, C. A., & Wang, Z. (2017) · Journal of Immunological Methods · doi:10.1016/j.jim.2017.05.008 · Cited by 43
Targeting tumor tolerance: A new hope for pancreatic cancer therapy?
Delitto, D., Wallet, S. M., & Hughes, S. J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.008 · Cited by 41
Cho, J., Ahn, S., Yoo, K. H., Kim, H. J., Choi, S., Jang, K., & Lee, J. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0373-4 · Cited by 40
Austin, E., Mamalis, A., Ho, D. S., & Jagdeo, J. R. (2017) · Archives of Dermatological Research · doi:10.1007/s00403-017-1720-9 · Cited by 40
Resistance to c-Kit inhibitors in melanoma: insights for future therapies
Carlino, M. S., Todd, J. R., & Rizos, H. (2014) · Oncoscience · doi:10.18632/oncoscience.51 · Cited by 37
Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206.
Hanson, D. C., Canniff, P. C., Primiano, M. J., Donovan, C. B., Gardner, J. P., Natoli, E. J., Morgan, R. W., Mather, R. J., Singleton, D. H., Hermes, P., et al. (2004) · Cancer Research · Cited by 37
Biteghe, F. A. N., & Davids, L. (2016) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2016.11.004 · Cited by 37
High frequency of brain metastases after adjuvant therapy for high‐risk melanoma
Samlowski, W. E., Moon, J., Witter, M., Atkins, M. B., Kirkwood, J. M., Othus, M. K. D., Ribas, A., Sondak, V. K., & Flaherty, L. E. (2017) · Cancer Medicine · doi:10.1002/cam4.1223 · Cited by 37
Immune Checkpoint Blockade and Interferon-α in Melanoma
Rafique, I., Kirkwood, J. M., & Tarhini, A. A. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.012 · Cited by 36
Weide, B., Martens, A., Wistuba‐Hamprecht, K., Zelba, H., Maier, L., Lipp, H., Klumpp, B. D., Soffel, D., Eigentler, T., & Garbe, C. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1944-0 · Cited by 35
Li, X., Wu, D., SHEN, J., Zhou, M., & Lü, Y. (2012) · Oncology Letters · doi:10.3892/ol.2012.986 · Cited by 33
Klemen, N. D., Feingold, P. L., Goff, S. L., Hughes, M. S., Kammula, U. S., Yang, J. C., Schrump, D. S., Rosenberg, S. A., & Sherry, R. M. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5537-0 · Cited by 32
Prével, C., Pellerano, M., Gonzalez‐Vera, J. A., Henri, P., Meunier, L., Vollaire, J., Josserand, V., & Morris, M. C. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.04.050 · Cited by 31
A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
Brohl, A. S., Khushalani, N. I., Eroglu, Z., Markowitz, J., Thapa, R., Chen, Y. A., Kudchadkar, R. R., & Weber, J. S. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0194-1 · Cited by 29
Pópulo, H., Caldas, R., Lopes, J. M., Pardal, J., Máximo, V., & Soares, P. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1045416 · Cited by 28
Self-citationSpecenier, P. M. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1249856 · Cited by 27
Role of interferon in melanoma: old hopes and new perspectives
Sanlorenzo, M., Vujic, I., Carnevale‐Schianca, F., Quaglino, P., Gammaitoni, L., Fierro, M. T., Aglietta, M., & Sangiolo, D. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1289169 · Cited by 25
Difference of interferon-α and interferon-β on melanoma growth and lymph node metastasis in mice
Roh, M. R., Zheng, Z., Kim, H. S., Jeung, H., Rha, S. Y., & Chung, K. Y. (2013) · Melanoma Research · doi:10.1097/cmr.0b013e32835e7713 · Cited by 21
Gâta, V. A., Lisencu, C. I., Vlad, C. I., Piciu, D., Irimie, A., & Achimaș-Cădariu, P. (2017) · PubMed · Cited by 21
The Menace of Melanoma: A Photodynamic Approach to Adjunctive Cancer Therapy
Davids, L. M., & Kleem, B. (2013) · InTech eBooks · doi:10.5772/53676 · Cited by 18
Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy
Mandalà, M., Tondini, C. A., Merelli, B., & Massi, D. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0282-0 · Cited by 16
Melanoma Resistance to Photodynamic Therapy
Sharma, S. K., Huang, Y., & Hamblin, M. R. (2014) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-12730-9_11 · Cited by 14
GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells
Pópulo, H., Tavares, S., Faustino, A., Nunes, J. B., Lopes, J. M., & Soares, P. (2013) · PeerJ · doi:10.7717/peerj.104 · Cited by 14
Self-citation[25] Induction of chick interferon: Procedures of the original experiments
Lindenmann, J. (1981) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(81)78115-1 · Cited by 11
Zarour, H. M., Tawbi, H. A.-H., Tarhini, A. A., Wang, H., Sander, C., Rose, A. E., Fourcade, J. J., Chauvin, J.-M., Sun, Z., Pagliano, O., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.e20018 · Cited by 8
Cited by
Trends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
Therapeutic Effects of Fucoidan: A Review on Recent Studies
Luthuli, S., Wu, S., Cheng, Y., Zheng, X., Wu, M., & Tong, H. (2019) · Marine Drugs · doi:10.3390/md17090487 · Cited by 391
Many ways to resistance: How melanoma cells evade targeted therapies
Kozar, I., Margue, C., Rothengatter, S., Haan, C., & Kreis, S. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.02.002 · Cited by 270
Current and future perspectives of PD-1/PDL-1 blockade in cancer immunotherapy
Makuku, R., Khalili, N., Razi, S., Keshavarz-Fathi, M., & Rezaei, N. (2021) · Journal of Immunology Research · doi:10.1155/2021/6661406 · Cited by 136
Anti-angiogenic effects of mangiferin and mechanism of action in metastatic melanoma
Delgado-Hernández, R., Hernández-Balmaseda, I., Rodeiro-Guerra, I., Cesar Rodriguez Gonzalez, J., De Wever, O., Logie, E., Declerck, K., Pérez-Novo, C., & Vanden Berghe, W. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000647 · Cited by 29
Metadata
- Authors
- Domingues, B., Lopes, J., Soares, P., & Populo, H.
- Venue
- ImmunoTargets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2018-06
- Volume
- Volume 7
- Pages
- 35-49
- ISSN
- 2253-1556 (ISSN-L)
- OpenAlex
- W2806295244
- Cited by
- 701
- References
- 161
- FWCI
- 24.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.